Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia

Neil Elliot Kay, Wenting Wu, Brian Kabat, Betsy LaPlant, Thomas S. Lin, John C. Byrd, Diane F Jelinek, Michael R. Grever, Clive S. Zent, Timothy G. Call, Tait D. Shanafelt

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

BACKGROUND: The combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) achieved an overall response (OR) rate >90%, with >40% complete responses (CRs) in patients with untreated chronic lymphocytic leukemia (CLL). METHODS: To evaluate whether the tolerability of this regimen could be enhanced without sacrificing efficacy, a phase 2 trial was conducted of P and R without C, using a higher P dose (4 mg/m2). Among the 33 patients enrolled, 82% were male, the median age was 65 years (9 patients were aged ≥70 years), and 64% were classified as having Rai stage III to IV disease. RESULTS: The OR rate was 76%, with 9 CRs (27%), 5 nodular partial responses, and 11 partial responses (PRs) reported. At the time of last follow-up, 29 of 33 patients were still alive at a median follow-up of 14 months (range, 1-34.8 months). Four (12%) patients experienced grade 3 or higher hematologic toxicity, and 5 (15%) experienced grade 3 or higher nonhematologic toxicity. Comparison of this trial with the previous PCR trial demonstrated that patients treated with PCR had a higher OR rate (91% vs 76%) and CR rate (41% vs 27%) compared with patients treated with PR. The median treatment-free survival for all accrued patients was notably longer in patients treated with PCR compared with PR (30 months vs 16 months). CONCLUSIONS: The findings of the current study suggest that increasing the dose of the purine nucleoside analogue does not eliminate the need for cyclophosphamide in chemoimmunotherapy for the treatment of CLL.

Original languageEnglish (US)
Pages (from-to)2180-2187
Number of pages8
JournalCancer
Volume116
Issue number9
DOIs
StatePublished - May 1 2010

Fingerprint

Pentostatin
B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Polymerase Chain Reaction
Cyclophosphamide
Purine Nucleosides
Rituximab

Keywords

  • B-cell chronic lymphocytic leukemia
  • Chemoimmunotherapy
  • Cyclophosphamide
  • Pentostatin
  • Response rates
  • Rituximab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kay, N. E., Wu, W., Kabat, B., LaPlant, B., Lin, T. S., Byrd, J. C., ... Shanafelt, T. D. (2010). Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer, 116(9), 2180-2187. https://doi.org/10.1002/cncr.25028

Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. / Kay, Neil Elliot; Wu, Wenting; Kabat, Brian; LaPlant, Betsy; Lin, Thomas S.; Byrd, John C.; Jelinek, Diane F; Grever, Michael R.; Zent, Clive S.; Call, Timothy G.; Shanafelt, Tait D.

In: Cancer, Vol. 116, No. 9, 01.05.2010, p. 2180-2187.

Research output: Contribution to journalArticle

Kay, NE, Wu, W, Kabat, B, LaPlant, B, Lin, TS, Byrd, JC, Jelinek, DF, Grever, MR, Zent, CS, Call, TG & Shanafelt, TD 2010, 'Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia', Cancer, vol. 116, no. 9, pp. 2180-2187. https://doi.org/10.1002/cncr.25028
Kay, Neil Elliot ; Wu, Wenting ; Kabat, Brian ; LaPlant, Betsy ; Lin, Thomas S. ; Byrd, John C. ; Jelinek, Diane F ; Grever, Michael R. ; Zent, Clive S. ; Call, Timothy G. ; Shanafelt, Tait D. / Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. In: Cancer. 2010 ; Vol. 116, No. 9. pp. 2180-2187.
@article{ea300305c4734f18aff3b39bf996579c,
title = "Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia",
abstract = "BACKGROUND: The combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) achieved an overall response (OR) rate >90{\%}, with >40{\%} complete responses (CRs) in patients with untreated chronic lymphocytic leukemia (CLL). METHODS: To evaluate whether the tolerability of this regimen could be enhanced without sacrificing efficacy, a phase 2 trial was conducted of P and R without C, using a higher P dose (4 mg/m2). Among the 33 patients enrolled, 82{\%} were male, the median age was 65 years (9 patients were aged ≥70 years), and 64{\%} were classified as having Rai stage III to IV disease. RESULTS: The OR rate was 76{\%}, with 9 CRs (27{\%}), 5 nodular partial responses, and 11 partial responses (PRs) reported. At the time of last follow-up, 29 of 33 patients were still alive at a median follow-up of 14 months (range, 1-34.8 months). Four (12{\%}) patients experienced grade 3 or higher hematologic toxicity, and 5 (15{\%}) experienced grade 3 or higher nonhematologic toxicity. Comparison of this trial with the previous PCR trial demonstrated that patients treated with PCR had a higher OR rate (91{\%} vs 76{\%}) and CR rate (41{\%} vs 27{\%}) compared with patients treated with PR. The median treatment-free survival for all accrued patients was notably longer in patients treated with PCR compared with PR (30 months vs 16 months). CONCLUSIONS: The findings of the current study suggest that increasing the dose of the purine nucleoside analogue does not eliminate the need for cyclophosphamide in chemoimmunotherapy for the treatment of CLL.",
keywords = "B-cell chronic lymphocytic leukemia, Chemoimmunotherapy, Cyclophosphamide, Pentostatin, Response rates, Rituximab",
author = "Kay, {Neil Elliot} and Wenting Wu and Brian Kabat and Betsy LaPlant and Lin, {Thomas S.} and Byrd, {John C.} and Jelinek, {Diane F} and Grever, {Michael R.} and Zent, {Clive S.} and Call, {Timothy G.} and Shanafelt, {Tait D.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1002/cncr.25028",
language = "English (US)",
volume = "116",
pages = "2180--2187",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia

AU - Kay, Neil Elliot

AU - Wu, Wenting

AU - Kabat, Brian

AU - LaPlant, Betsy

AU - Lin, Thomas S.

AU - Byrd, John C.

AU - Jelinek, Diane F

AU - Grever, Michael R.

AU - Zent, Clive S.

AU - Call, Timothy G.

AU - Shanafelt, Tait D.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - BACKGROUND: The combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) achieved an overall response (OR) rate >90%, with >40% complete responses (CRs) in patients with untreated chronic lymphocytic leukemia (CLL). METHODS: To evaluate whether the tolerability of this regimen could be enhanced without sacrificing efficacy, a phase 2 trial was conducted of P and R without C, using a higher P dose (4 mg/m2). Among the 33 patients enrolled, 82% were male, the median age was 65 years (9 patients were aged ≥70 years), and 64% were classified as having Rai stage III to IV disease. RESULTS: The OR rate was 76%, with 9 CRs (27%), 5 nodular partial responses, and 11 partial responses (PRs) reported. At the time of last follow-up, 29 of 33 patients were still alive at a median follow-up of 14 months (range, 1-34.8 months). Four (12%) patients experienced grade 3 or higher hematologic toxicity, and 5 (15%) experienced grade 3 or higher nonhematologic toxicity. Comparison of this trial with the previous PCR trial demonstrated that patients treated with PCR had a higher OR rate (91% vs 76%) and CR rate (41% vs 27%) compared with patients treated with PR. The median treatment-free survival for all accrued patients was notably longer in patients treated with PCR compared with PR (30 months vs 16 months). CONCLUSIONS: The findings of the current study suggest that increasing the dose of the purine nucleoside analogue does not eliminate the need for cyclophosphamide in chemoimmunotherapy for the treatment of CLL.

AB - BACKGROUND: The combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) achieved an overall response (OR) rate >90%, with >40% complete responses (CRs) in patients with untreated chronic lymphocytic leukemia (CLL). METHODS: To evaluate whether the tolerability of this regimen could be enhanced without sacrificing efficacy, a phase 2 trial was conducted of P and R without C, using a higher P dose (4 mg/m2). Among the 33 patients enrolled, 82% were male, the median age was 65 years (9 patients were aged ≥70 years), and 64% were classified as having Rai stage III to IV disease. RESULTS: The OR rate was 76%, with 9 CRs (27%), 5 nodular partial responses, and 11 partial responses (PRs) reported. At the time of last follow-up, 29 of 33 patients were still alive at a median follow-up of 14 months (range, 1-34.8 months). Four (12%) patients experienced grade 3 or higher hematologic toxicity, and 5 (15%) experienced grade 3 or higher nonhematologic toxicity. Comparison of this trial with the previous PCR trial demonstrated that patients treated with PCR had a higher OR rate (91% vs 76%) and CR rate (41% vs 27%) compared with patients treated with PR. The median treatment-free survival for all accrued patients was notably longer in patients treated with PCR compared with PR (30 months vs 16 months). CONCLUSIONS: The findings of the current study suggest that increasing the dose of the purine nucleoside analogue does not eliminate the need for cyclophosphamide in chemoimmunotherapy for the treatment of CLL.

KW - B-cell chronic lymphocytic leukemia

KW - Chemoimmunotherapy

KW - Cyclophosphamide

KW - Pentostatin

KW - Response rates

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=77951456080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951456080&partnerID=8YFLogxK

U2 - 10.1002/cncr.25028

DO - 10.1002/cncr.25028

M3 - Article

VL - 116

SP - 2180

EP - 2187

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -